Insight journal - Dealtalk

Rumour mill has it that Shire is looking to acquire NPS Pharmaceuticals

Posted on 02 June 2014

Tags: , ,

London-listed drugmaker Shire is considering a bid for New Jersey-based NPS Pharmaceuticals, FT Alphaville reported on Friday citing sources.

Shire has been working with advisers and held internal discussions about a potential cash offer for NPS, a rare disease specialist, valuing the business at just over $4 billion, the Financial Times blog said.

Shares in Nasdaq-listed NPS were trading 15.5 percent higher at 1500 GMT giving the company a market capitalisation of $2.92 billion. Shares in Shire were trading down 1.4 percent.

View the article at Reuters

For further deal information visit Current Agreements (subscription required)

 

Related

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply